Elutia (ELUT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors, David Colpman and Kevin Rakin, is up for shareholder vote.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is proposed.
Approval sought for the First Amendment to the Amended and Restated 2020 Incentive Award Plan.
Advisory vote on executive compensation ("say on pay") and on the frequency of future say-on-pay votes are included.
Board of directors and corporate governance
Board recommends voting for all director nominees and for all proposals presented.
Shareholders may withhold authority for individual nominees or vote for all.
Executive compensation and say-on-pay
Advisory, non-binding vote on executive compensation is included.
Shareholders to select preferred frequency (one, two, or three years) for future say-on-pay votes.
Latest events from Elutia
- Up to $26M in funding secured, improved margins, and strong surgeon demand for NXT-41x.ELUT
Q2 2026 - New drug-eluting biologic envelope gains traction with major partner and strong clinical benefits.ELUT
Planet MicroCap Showcase: VEGAS 2025 - EluPro's rapid adoption and a robust pipeline position the company for significant growth.ELUT
Cantor Global Healthcare Conference 2025 - Drug-eluting mesh targets high breast reconstruction infection rates, with launch expected next year.ELUT
Planet MicroCap Las Vegas 2026 - Antibiotic-eluting matrix targets high breast reconstruction infection rates in a $1.5B market.ELUT
16th Annual LD Micro Invitational Conference - Net sales up 6%, gross margin improved, and NXT-41/41x on track for 2026–2027 launch.ELUT
Q1 2026 - Shareholders will vote on director elections, auditor ratification, and key compensation matters.ELUT
Proxy filing - Q4 revenue up 16%, BioEnvelope sale drove debt repayment, and NXT-41x FDA process advanced.ELUT
Q4 2025 - FDA clearance for EluPro and improved margins offset by a $28.2M net loss and going concern risks.ELUT
Q2 2024